DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
1777 Hardee Ave SW Atlanta, GA 30310 (404)253-1284 Fax:(404)669-4443	5/4/2026-5/12/2026*
	FEI NUMBER 3002746446

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
John W. McCall, PhD, Owner, Chief Scientific Officer

FIRM NAME	STREET ADDRESS
TRS Labs, Inc.	215 Paradise Blvd.
CITY, STATE, ZIP CODE, COUNTRY Athens, GA 30607	TYPE ESTABLISHMENT INSPECTED Nonclinical Laboratory

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:
This observation relates to protocol number (b) (4) Non-Clinical Laboratory Study (GLP): Safety Evaluation (b) (4)
(b) (4)
(b) (4)

OBSERVATION 1

The quality assurance unit failed to determine whether any deviations from approved protocols or standard operating procedures had been made without proper authorization and documentation.

Specifically,

The testing facility did not take (b) (4) testing at the (b) (4) f protocol (b) (4) The applicable SOP at the time of the study, SOP 6.12 Revision 5, Section 2.0, specified that (b) (4)

*DATES OF INSPECTION

5/04/2026(Mon), 5/05/2026(Tue), 5/06/2026(Wed), 5/07/2026(Thu), 5/08/2026(Fri), 5/11/2026(Mon), 5/12/2026(Tue)

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE		DATE ISSUED
	Marshall A Naimo, Investigator	X Marshall A Naimo Investigator Signed By: MARSHALL A. NAIMO JR -S Date Signed: 05-12-2026 16:03:27	5/12/2026

The observations of objectionable conditions and practices listed on the front of this form are reported:

1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."